155 related articles for article (PubMed ID: 2502207)
1. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
2. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
4. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
5. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
6. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
7. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
8. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
Weitz JI; Leslie B; Hudoba M
Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
[TBL] [Abstract][Full Text] [Related]
9. Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1991 Nov; 66(5):592-7. PubMed ID: 1839474
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma.
Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925
[TBL] [Abstract][Full Text] [Related]
11. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Prager NA; Abendschein DR; McKenzie CR; Eisenberg PR
Circulation; 1995 Aug; 92(4):962-7. PubMed ID: 7641380
[TBL] [Abstract][Full Text] [Related]
12. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.
Rudd MA; George D; Johnstone MT; Moore RT; Collins L; Rabbani LE; Loscalzo J
Circ Res; 1992 Apr; 70(4):829-34. PubMed ID: 1551206
[TBL] [Abstract][Full Text] [Related]
13. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.
Gandossi E; Lunven C; Berry CN
Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104
[TBL] [Abstract][Full Text] [Related]
14. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
Bode C; Hudelmayer M; Mehwald P; Bauer S; Freitag M; von Hodenberg E; Newell JB; Kübler W; Haber E; Runge MS
Circulation; 1994 Oct; 90(4):1956-63. PubMed ID: 7923685
[TBL] [Abstract][Full Text] [Related]
15. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors.
Gandossi E; Lunven C; Gauffeny C; Roome NO; Berry CN
Thromb Haemost; 1998 Nov; 80(5):840-4. PubMed ID: 9843181
[TBL] [Abstract][Full Text] [Related]
16. Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin.
Ren K; Gong H; Hu L; He K; Yu A; Hu S; Liang S; Zhou C; Wu C
J Thromb Thrombolysis; 2021 Oct; 52(3):880-888. PubMed ID: 33826053
[TBL] [Abstract][Full Text] [Related]
17. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
18. Effect of heparin on the interaction between thrombin and hirudin.
Stone SR; Hofsteenge J
Eur J Biochem; 1987 Dec; 169(2):373-6. PubMed ID: 3691497
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Callas D; Bacher P; Iqbal O; Hoppensteadt D; Fareed J
Thromb Res; 1994 May; 74(3):193-205. PubMed ID: 8042188
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
